View Information Collection Request (ICR) Package

OMB Control No: 0910-0681	ICR Reference No: 201403-0910-008
Status: Historical Active	Previous ICR Reference No: 201101-0910-002
Agency/Subagency: HHS/FDA	Agency Tracking No: 21601
Title: Guidance for Industry: Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Whole Blood and Blood Components Intended for Transfusion
Type of Information Collection: Extension without change of a currently approved collection	Common Form ICR: No
Type of Review Request: Regular
OIRA Conclusion Action: Approved without change	Conclusion Date: 04/29/2014
	Date Received in OIRA: 03/21/2014
Terms of Clearance:

	Inventory as of this Action	Requested	Previously Approved
Expiration Date	04/30/2017	36 Months From Approved	04/30/2014
Responses	1	0	1
Time Burden (Hours)	1	0	1
Cost Burden (Dollars)	0	0	0

Abstract: The guidance recommends that establishments that manufacture Whole Blood and blood components intended for transfusion should notify consignees of all previously collected in-date blood and blood components to quarantine and return the blood and blood components to establishments or to destroy them within 3 calendar days after a donor tests repeatedly reactive by a licensed test for T. cruzi antibody. When establishments identify a donor who is repeatedly reactive by a licensed test for T. cruzi antibodies and for whom there is additional information indicating risk of T. cruzi infection, such as testing positive on a licensed supplemental test (when such test is available) or until such test is available, information that the donor or donor's mother resided in an area endemic for Chagas disease (Mexico, Central and South America) or as a result of other medical diagnostic testing of the donor indicating T. cruzi infection, FDA recommends that the establishment notify consignees of all previously distributed blood and blood components collected during the "lookback" period, and, if blood or blood components were transfused, to encourage consignees to notify the recipient's physician of record of a possible increased risk of T. cruzi infection. The notification of consignees and of the recipient's physician of record is intended to provide the necessary information regarding possible increased risk of T. cruzi infection. All donors who test repeatedly reactive should be counseled to seek a physician's advice. It also may be helpful to refer them to their state and local health departments or to other appropriate community resources.

Authorizing Statute(s): US Code: 42 USC 262 Name of Law: PHS Act
US Code: 21 USC 301 Name of Law: Federal Food Drug and Cosmetic Act

Citations for New Statutory Requirements: None

Associated Rulemaking Information
RIN:	Stage of Rulemaking:	Federal Register Citation:	Date:
	Not associated with rulemaking

Federal Register Notices & Comments
60-day Notice:	Federal Register Citation:	Citation Date:
	78 FR 46954	08/02/2013
30-day Notice:	Federal Register Citation:	Citation Date:
	79 FR 12506	03/05/2014
Did the Agency receive public comments on this ICR? No

ICR Summary of Burden

	Total Approved	Previously Approved
Annual Number of Responses	1	1
Annual Time Burden (Hours)	1	1
Annual Cost Burden (Dollars)	0	0

Burden increases because of Program Change due to Agency Discretion: No

Burden Increase Due to:

Burden decreases because of Program Change due to Agency Discretion: No

Burden Reduction Due to:

Short Statement:

Annual Cost to Federal Government: $0

Does this IC contain surveys, censuses, or employ statistical methods? No

Is the Supporting Statement intended to be a Privacy Impact Assessment required by the E-Government Act of 2002? No

Is this ICR related to the Affordable Care Act [Pub. L. 111-148 & 111-152]? No

Is this ICR related to the Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]? No

Is this ICR related to the American Recovery and Reinvestment Act of 2009 (ARRA)? No

Is this ICR related to the Pandemic Response? Uncollected

Agency Contact: ILa Mizrachi 301 796-7726 ila.mizrachi@fda.hhs.gov

View ICR - OIRA Conclusion